Novel multitargeted Imidazo[1,2-a]pyridine-1,3,4-oxadiazole hybrids: design, synthesis and biological evaluation as anti-Alzheimer's agents.

AIMS: To design, synthesize, and evaluate novel imidazo[1,2-a]pyridine derivatives as dual acetylcholinesterase (AChE) and β-secretase (BACE1) inhibitors for potential Alzheimer's disease (AD) therapy.

MATERIALS AND

METHODS

A series of imidazo[1,2-a]pyridine derivatives (DS1-DS15) were synthesized via cyclization using various aryl and heteroaryl acids and characterized by MP, TLC, FTIR, MS, and 1H/13C NMR spectroscopy. Molecular docking studies were performed against AChE (PDB ID: 4EY7) and BACE1 (PDB ID: 4ACU). Pharmacokinetic properties were predicted using pkCSM, and molecular dynamics simulations were conducted for the lead compound. In vitro inhibitory activities were determined by IC50 values. In vivo anti-AD activity was evaluated in male Sprague Dawley rats using biochemical assays and histological analysis.

RESULTS

Compound DS7 showed the highest binding affinity toward both targets with stable protein-ligand interactions. It exhibited potent AChE inhibition (IC50 = 0.054 µM) and significant BACE1 inhibition (IC50 = 5.67 µM). In vivo studies demonstrated significant reversal of AD-associated biochemical and histopathological alterations at high dose.

CONCLUSION

DS7 emerged as a promising dual AChE/BACE1 inhibitor and a potential lead candidate for further optimization in AD drug development.